Sodium Phosphate P 32

Pronunciation: SO-dee-uhm FOSS-fate P 32
Class: Radiopharmaceutical

Trade Names:
Sodium Phosphate P 32
- Injection 0.67 mCi/mL

Phoslax (Canada)
Phosphates Solution (Canada)

Pharmacology

Phosphorus is necessary to the metabolic and proliferative activity of cells. Radioactive phosphorus concentrates to a very high degree in rapidly proliferating tissue. Sodium phosphate P 32 decays by beta emission with a physical half-life of 14.3 days. The mean energy of the sodium phosphate P 32 beta particle is 695 keV.

Indications and Usage

Treatment of polycythemia vera, chronic myelocytic leukemia, and chronic lymphocytic leukemia; skeletal metastases.

Contraindications

Do not use as part of sequential treatment with a chemotherapeutic agent. Do not administer when the leukocyte count is less than 5,000/mm 3 or platelet count is less than 150,000/mm 3 . Do not administer when the leukocyte count is less than 20,000/mm 3 . Usually not administered when the leukocyte count is less than 5,000/mm 3 and the platelet count is less than 100,000/mm 3 .

Dosage and Administration

Administer IV. Do not administer as an intracavity injection. Oral administration of high-specific-activity sodium phosphate P 32 in the fasting state may equal IV administration.

Polycythemia Vera
Adults

IV 1 to 8 mCi. Individualize. Repeat doses depending upon stage of disease and size of patient.

Chronic Leukemia
Adults

IV 6 to 15 mCi usually with concomitant hormone manipulation.

General Advice

  • Dose will be prepared by a person authorized by the Nuclear Regulatory Commission and will be delivered ready to administer.
  • Following administration return all equipment to transport container for disposal.

Storage/Stability

Store in transport container until time of administration.

Drug Interactions

None well documented.

Laboratory Test Interactions

None well documented.

Adverse Reactions

None well documented.

Precautions

Pregnancy

Category C .

Lactation

Discontinue breast-feeding during therapy.

Children

Safety and efficacy have not been established.

Retinoblastomas

Sodium phosphate P 32 does not usually localize in retinoblastomas.

Radiation exposure

Ensure minimum radiation exposure to patients and occupational workers consistent with proper patient management.

Overdosage

Symptoms

May produce serious effects on the hematopoietic system.

Patient Information

  • Advise patient, family, or caregiver that medication will be prepared and administered by health care provider in a health care setting.
  • Advise patient, family, or caregiver that medication may be repeated depending on response to therapy and size of the patient. It is usually administered 1 time only.
  • Advise patient to immediately report any of the following to the health care provider: fever, chills, or other signs of infection; unusual bruising or bleeding.

Copyright © 2009 Wolters Kluwer Health.

Hide
(web3)